First-quarter 2021 sales worldwide: $10.5B, +33% on an organic basis*

Sales performance across Abbott:
- Diagnostics: +114.8%
- Nutrition: +6.4%
- Medical Devices: +8.8%

Full-year 2021 guidance remains unchanged: Adjusted diluted EPS at least $5.00, reflecting growth of more than 35% versus prior year.

Growth and momentum across our product pipeline:

Cardiovascular:
- Pipeline advances in key segments: Strong growth in structural heart, electrophysiology.
- Expanded reimbursement for MitraClip®.
- CE Mark for new gen-TiClipp® device.

Diabetes care:
- Strong growth, global leadership.
- FreeStyle Libre system now has 3+ million users worldwide.

Diagnostics:
- New breakthroughs in COVID-19 testing.
- FDA EUA for over-the-counter BinaxNOW™ COVID-19 Self Test®
- Provided nearly 700 million COVID-19 tests since the start of the pandemic.

Pipeline advances in key segments:
- Strong growth in structural heart, electrophysiology.
- Expanded reimbursement for MitraClip.
- CE Mark for new gen-TiClipp device.

Global leadership:
- Diabetes Care grew 24% this quarter.
- FreeStyle Libre system now has 3+ million users worldwide.

Growth and momentum across our product pipeline:

Cardiovascular:
- Pipeline advances in key segments: Strong growth in structural heart, electrophysiology.
- Expanded reimbursement for MitraClip.
- CE Mark for new gen-TiClipp device.

Diabetes care:
- Strong growth, global leadership.
- FreeStyle Libre system now has 3+ million users worldwide.

Diagnostics:
- New breakthroughs in COVID-19 testing.
- FDA EUA for over-the-counter BinaxNOW™ COVID-19 Self Test®
- Provided nearly 700 million COVID-19 tests since the start of the pandemic.